Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry.
Rafael Toledano-DelgadoIrene García-MoralesBeatriz Parejo-CarbonellAdolfo Jiménez-HueteDavid Herrera-RamirezAyoze González-HernándezFernando Ayuga LoroEstevo SantamarinaManuel ToledoJoaquín OjedaJuan José PozaAlbert MolinsPau GinerJosé Carlos Estévez MaríaMaría Dolores Castro-VilanovaJorge ZuritaRosa Ana Saiz-DiazAsier Gómez-IbañezJuan Rodriguez-UrangaAntonio Gil-NagelDulce CamposÁlvaro Sánchez-LarsenMaria José Aguilar-Amat PriorJosé Angel Mauri LlerdaNuria Huertas GonzálezNuria García-BarragánPublished in: Epilepsia (2020)
PER demonstrated good effectiveness and a good safety profile when used as primary therapy or conversion to monotherapy at relatively low doses, in a clinical setting with patients with focal seizures and GTCS.